Table 2 Baseline characteristics of participants by LDL-C/apoB concordance/discordance

N

80

37

87

198

Age, year

64.7 ± 12.8

64.8 ± 15.1

66.5 ± 13.6

66.4 ± 12.4

0.684

Male, n (%)

52 (65.0)

22 (59.5)

50 (57.5)

115 (58.1)

0.725

Smoking, n (%)

32 (40.0)

14 (37.8)

32 (36.8)

82 (41.4)

0.895

Drinking, n (%)

27 (33.8)

9 (24.3)

24 (27.6)

43 (21.7)

0.206

Hypertension, n (%)

63 (78.8)

24 (64.9)

65 (74.7)

60 (80.8)

0.164

DM, n (%)

31 (38.8)

13 (35.1)

28 (32.2)

86 (43.4)

0.315

SBP, mmHg

122.3 ± 16.3

126.2 ± 16.7

128.9 ± 15.8

134.6 ± 18.3

0.000

DBP, mmHg

72.5 ± 10.6

72.8 ± 8.2

73.8 ± 9.8

76.9 ± 9.9

0.002

BMI, kg/m²

25.0 ± 3.1

25.5 ± 3.8

25.3 ± 3.1

25.9 ± 3.5

0.236

FBG, mmol/L

5.9 ± 2.4

5.8 ± 1.7

5.6 ± 1.8

6.1 ± 2.5

0.237

HDL-C, mmol/L

1.22 ± 0.35

1.19 ± 0.30

1.23 ± 0.34

1.15 ± 0.29

0.054

LDL-C, mmol/L

1.51 ± 0.22

1.59 ± 0.25

2.29 ± 0.45

2.97 ± 0.66

0.000^*

Non-HDL-C, mmol/L

1.93 ± 0.44

3.46 ± 0.81

2.61 ± 0.39

3.64 ± 0.74

0.000^#

TC, mmol/L

3.15 ± 0.51

4.56 ± 0.86

3.83 ± 0.48

4.79 ± 0.76

0.000

TG, mmol/L

1.48 ± 1.62

1.82 ± 1.34

1.49 ± 0.76

2.14 ± 1.67

0.000

apoB, mmol/L

0.58 ± 0.10

0.95 ± 0.15

0.72 ± 0.06

0.98 ± 0.15

0.000^#

UA, μmol/L

343.6 ± 75.5

358.0 ± 76.7

346.8 ± 90.4

357.8 ± 89.0

0.062

homocysteine, mmol/L

14.3 ± 7.0

14.4 ± 9.3

14.7 ± 7.0

14.9 ± 8.0

0.946

eGFR, mL/(min·1.73 m²)

94.2 ± 15.6

92.7 ± 16.8

90.4 ± 16.4

89.8 ± 17.7

0.232

HGB, g/L

136.7 ± 14.0

135.3 ± 16.1

135.9 ± 15.4

136.4 ± 15.9

0.060

HR, bpm

67.4 ± 9.7

68.3 ± 10.1

66.9 ± 8.7

68.4 ± 9.7

0.064

Lipid-lowering therapy, n (%)

54 (67.5)

17 (45.9)

39 (44.8)

70 (35.4)

0.000

baPWV, cm/s

1525.7 ± 327.0

1733.9 ± 609.4

1684.0 ± 364.2

1797.3 ± 380.4

0.000